

## ORIGINAL ARTICLE

# A Pooled Analysis of Diagnostic Value of $^{99m}\text{Tc}$ -Ubiquicidin (UBI) Scintigraphy in Detection of an Infectious Process

Afshin Ostovar, MD, PhD,\* Mahsan Assadi, MD,\* Katayoun Vahdat, MD,\* Iraj Nabipour, MD,\* Hamid Javadi, MD,† Mohammad Eftekhari, MD,‡ and Majid Assadi, MD§

**Purpose:** Although the data are promising from limited studies with technetium- $^{99m}\text{Tc}$  ubiquicidin ( $^{99m}\text{Tc}$ -UBI) scintigraphy in detection of infection in humans, these studies have had a limited sample size. This study was conducted to provide a systematic review and meta-analysis of the reported diagnostic accuracy of  $^{99m}\text{Tc}$ -UBI scintigraphy in detection of an infectious process.

**Materials and Methods:** The PubMed/MEDLINE, Web of Science, EMBASE, and Google Scholar literature databases were systematically searched to find the relevant human studies on  $^{99m}\text{Tc}$ -UBI scintigraphy. For each eligible study, the true-positive, false-positive, true-negative, and false-negative findings at  $^{99m}\text{Tc}$ -UBI scintigraphy were recorded, and the overall statistical parameters were acquired.

**Result:** Ten studies carried out from 2004 to 2010 were included in the analysis. The pooled data sensitivity was 94.5 % and with a 95% confidence interval of 91.2%–96.8%. The pooled specificity was still as high as about 92.7%. The range of reported specificity was from 80% to 100%. The overall accuracy was 93.7% (95% CI: 91.2%–95.7%).

**Conclusion:** The study demonstrated that  $^{99m}\text{Tc}$ -UBI scintigraphy can be used to identify an infectious process with admirable accuracy in early views; however, further investigations are recommended.

**Key Words:**  $^{99m}\text{Tc}$ -UBI scan, antimicrobial peptides, infection

(*Clin Nucl Med* 2013;38: 413–416)

The prompt and timely clinical diagnosis of infection can be challenging, but it is associated in a crucial way with a patient's care management. Current available radiopharmaceuticals are often unable to differentiate between sterile inflammation and infection. Several pharmaceuticals labeled with various radioisotopes, such as liposomes labeled with technetium- $^{99m}\text{Tc}$ ,<sup>1</sup> immunoglobulins,<sup>2,3</sup> the avidin-biotin system,<sup>4</sup> antigranulocyte antibodies and antibody fragments, chemotactic peptides, cytokines, interleukins, platelet factor-4, and ciprofloxacin labeled with  $^{99m}\text{Tc}$ ,<sup>5</sup> have been applied, but an optimal radiotracer has not yet been established. Therefore, autologous leukocytes labeled with  $^{111}\text{In}$  or  $^{99m}\text{Tc}$ -HMPAO are still considered the gold standard despite their limitations.<sup>6</sup> Consequently, the practice of directly targeting infectious agents with radiolabeled antibiotics or antimicrobial peptides was introduced,<sup>7</sup> and a number of radiolabeled peptides have been assessed.<sup>8,9</sup> Among the several radiolabeled

peptides options,  $^{99m}\text{Tc}$ -labeled cationic antimicrobial peptides originating from ubiquicidin (UBI) are increasingly used in the diagnostic evaluation of patients.<sup>10,11</sup>

Although results from limited preclinical and pilot studies in patients are promising,<sup>12,13</sup> they had a limited sample size. So we have performed a meta-analysis of diagnostic studies regarding the accuracy of  $^{99m}\text{Tc}$ -UBI 29–41 scintigraphy in the identification of infection.

## MATERIALS AND METHODS

### Identification and Eligibility of Pertinent Investigations

An attempt was made to identify all investigations regarding the diagnostic accuracy of ubiquicidin (UBI) labeled with  $^{99m}\text{Tc}$  for the detection of infection in patients.

All pertinent investigations were included, not considering the type of UBI used and regardless of the location of disease. The PubMed/MEDLINE, Web of Science, EMBASE, and Google Scholar literature records were systematically searched for publications from January 1965 up to September 2012. The search strategy was based on the terms “ $^{99m}\text{Tc}$ -ubiquicidin scintigraphy,” “ $^{99m}\text{Tc}$ -UBI scintigraphy,” “antimicrobial peptides scan using UBI,” “ubiquicidin scan,” and “UBI scan.” Experimental investigations on animals were excluded.

### Data Extraction

First, 2 researchers (A.O., M.A.) obtained data from eligible investigations separately and discussed discrepancies, and when agreement was not attained, a third researcher (M.A.) helped to resolve the difference. For each study, several items were recorded such as authors' names, publication year, number of eligible patients, inclusion and exclusion criteria, study design (prospective, retrospective, or unclear), demographic characteristics of patients, location of disease, type of synthetic fragments UBI (UBI 18–35 or UBI 29–41), methods used for the interpretation of the results (qualitative or semiquantitative), and the number of readers who interpreted the final diagnosis. The explanation of the reference method used to document infection was noted. The quality of evidence using the Critical Appraisal Skills Programme tool for diagnostic tests was also considered.<sup>14</sup>

### Statistical Analysis

For each study, the number of true-positive, false-positive, true-negative, and false-negative findings at  $^{99m}\text{Tc}$ -UBI scintigraphy, as compared with the standard method, was recorded in a  $2 \times 2$  table. We calculated true-positive (TP), true-negative (TN), false-positive (FP), and false-negative (FN) values by summing up the individuals of each category from all studies included. Then sensitivity was calculated as  $\text{TP}/(\text{TP} + \text{FN})$  and specificity as  $\text{TN}/(\text{TN} + \text{FP})$ . The accuracy was also

Received for publication October 10, 2012; revision accepted December 17, 2012.

From the \*Department of Infectious Diseases, The Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr; †Golestan Research Center of Gastroenterology and Hepatology (GRCGH), Golestan University of Medical Sciences (GUOMS),

Gorgan; ‡Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran; and §The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran.

Conflicts of interest and sources of funding: none declared.

Reprints: Majid Assadi, MD, The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr 3631, Iran. E-mail: asadi@bpums.ac.ir.

Copyright © 2013 by Lippincott Williams & Wilkins  
ISSN: 0363-9762/13/3806-0413

**TABLE 1.** Characteristics of Participants Included in the Studies

Study	Study Design	Mean Age; Range, yr	Men/Women	Reported Disease(s)
Assadi et al, <sup>15</sup> 2011	Prospective	48.9; 20–69	12/8	Suspicion of osteomyelitis, due to diabetic foot ulcers inflammation at the site of prosthesis, or bone fractures
Akhtar et al, <sup>16</sup> 2005	Prospective	31.7; 5–75	9/9	Suspected bone, soft-tissue, or prosthesis infections
Aryana et al, <sup>17</sup> 2012	Prospective	47; 20–79	18/16	Painful total hip prosthesis
Gandomkar et al, <sup>12</sup> 2008	Prospective	55; 35–75	5/2	Suspected bone or soft-tissue infections, osteomyelitis, cellulitis
Arteaga de Murphy et al, <sup>18</sup> 2010	Prospective	45; 18–88	56/92	FUO, osteomyelitis, diabetic foot, prosthesis infection, septic arthritis, bacteremia, suspected bone infection
Sepulveda-Mendez et al, <sup>13</sup> 2010	Retrospective	NR	NR	FUO
Dillmann-Arroyo et al, <sup>19</sup> 2011	Retrospective	50; NR	15/12	Suspected vertebral osteomyelitis
Melendez-Alafort et al, <sup>20</sup> 2004	Prospective	11.2; 2–15	4/2	Suspected bone infection
Fard-Esfahani et al, <sup>21</sup> 2010	Prospective	58; 48–79	10/5	Suspicion of osteomyelitis due to diabetic foot
Vallejo et al, <sup>22</sup> 2008	Prospective	50; 27–65	8/5	Suspected mediastinitis after cardiac surgery

NR indicates not reported; FUO, fever of unknown origin.

calculated as  $TP + TN / TP + TN + FP + FN$ . The confidence intervals of proportions were calculated using the Exact Binomial Method. The data analysis was carried out using STATA software, version 11 (StataCorp, College Station, TX, USA).

## RESULTS

Ten studies carried out from 2004 to 2010 were included in the analysis. The characteristics of these studies are shown in Tables 1, 2, and 3.

**Sensitivity:** Six out of 10 studies reported a perfect sensitivity for the technique. The sensitivities for others were from 40% to 97.5%. The pooled data sensitivity was 94.5% and with a 95% confidence interval of 91.2%–96.8%.

**Specificity:** Unlike sensitivity, the specificity is heterogeneous among the studies; however, the pooled specificity is still as high as about 92.7%. The range of reported specificity was from 80% to 100%, and only 2 studies reported a perfect specificity.

The values for all included studies and summary values have been summarized in Table 3.

## DISCUSSION

An infection process that includes bone, soft tissue, and orthopedic device infection is a critical problem that needs rapid diagnosis and treatment, especially with an incremental growth in resistance to new broad-spectrum antibiotic drugs.<sup>5</sup> The diagnosis of

an infection process is often not clear-cut, and it is associated with the severity of bone or soft-tissue involvement as well as with the host's reaction to pathogenic agents.<sup>23</sup>

Nuclear medicine techniques play an important role in this field, and several radiopharmaceuticals have been applied in the past, such as immunoglobulins,<sup>2,3</sup> liposomes, ciprofloxacin labeled with <sup>99m</sup>Tc,<sup>1</sup> the avidin-biotin system,<sup>4</sup> antigranulocyte antibodies and antibody fragments, chemotactic peptides, cytokines, interleukins, and platelet factor-4<sup>5</sup>; nevertheless, the optimal radiopharmaceutical has not yet been developed.

The optimal radiotracer should facilitate early diagnosis, should result in little absorbed radiation exposure, and should enable the differentiation of inflammation from infection.<sup>24</sup> Safety, cheapness, availability, and fast clearance from the blood and the body are further characteristics of an ideal radiopharmaceutical. Moreover, it should be simple and rapid in preparation.<sup>24</sup> Almost all present available radiopharmaceuticals possess some of these criteria, but up to now, no single radiotracer is known in clinical practice that can enable undoubted discrimination of infection from sterile inflammation.<sup>24</sup>

However, among all radiotracers, antimicrobial peptides that attach directly to bacteria are preferred, relative to other radiopharmaceuticals,<sup>16</sup> and among all the human-derived antimicrobial peptides tested, the UBI 29–41 has demonstrated the greatest promise.

<sup>99m</sup>Tc-labeled UBI 29–41 is a small synthetic peptide (amino acid sequence TGRAKRRMQYNRR; 1693 Da), which originated

**TABLE 2.** Characteristics of <sup>99m</sup>Tc-UBI Scintigraphy in Included Diagnostic Studies

Study	<sup>99m</sup> Tc (MBq)	Type of Synthetic Fragments UBI	Scanning Time, min	No. of Readers	Analysis	Blinding	Reference Standard
Assadi et al, <sup>15</sup> 2011	740	29–41	1–15, 30, 45, 60, 120, 240	2	SQ, Q	Yes	C, FU, H, M, R
Akhtar et al, <sup>16</sup> 2005	370–400	29–41	1–10, 30, 60, 120, 240	NR	SQ, Q	Yes	C, M, R
Aryana et al, <sup>17</sup> 2012	740	29–41	1–30	2	SQ, Q	Yes	C, FU, H, M, R
Gandomkar et al, <sup>12</sup> 2008	555–740	29–41	1–45, 30, 60, 120	NR	SQ, Q	Yes	C, FU, M, R
Arteaga de Murphy et al, <sup>18</sup> 2010	555–740	29–41	30, 120, 240, 1440	2–3	SQ, Q	Yes	C, R
Sepulveda-Mendez et al, <sup>13</sup> 2010	370–740	29–41	120, 360	2	Q	Yes	C, FU, M, R
Dillmann-Arroyo et al, <sup>19</sup> 2011	NR	29–41	120	2	Q	Yes	C, FU, H, M, R
Melendez-Alafort et al, <sup>20</sup> 2004	74–222	29–41	1, 30, 120, 240, 1440	3	SQ, Q	Yes	H, R
Fard-Esfahani et al, <sup>21</sup> 2010	555–740	29–41	1–10, 60, 120	3	Q	Yes	C
Vallejo et al, <sup>22</sup> 2008	740	29–41	120	2	SQ, Q	Yes	C, FU

NR indicates not reported; SQ, semiquantitative; Q, qualitative; C, culture; FU, clinical follow-up; H, histologic; M, microbiologic or laboratory examination other than culture; R, radiologic examination, including radiography, CT, MR imaging, and scintigraphy.

**TABLE 3.** The Summary of Original Studies Included in the Analysis

Study	Max T/NT Time, min	Max T/NT (Mean or Range)	Case	TP	TN	FP	FN	Se% (CI)	Sp% (CI)	Ac% (CI)
Assadi et al, <sup>15</sup> 2011	15	1.54–2.94	20	17	3	0	0	100	100	100
Akhtar et al, <sup>16</sup> 2005	30	2.75	18	14	3	1	0	100	80	94.4
Aryana et al, <sup>17</sup> 2012	1–30	1.90	34	6	24	4	0	100	85.7	88.2
Gandomkar et al, <sup>12</sup> 2008	30	2.10	7	5	2	0	0	100	100	100
Arteaga de Murphy et al, <sup>18</sup> 2010	30	2.1–2.8	148	77	64	4	3	96.3	94.1	95.3
Sepulveda-Mendez et al, <sup>13</sup> 2010	—	—	207	118	82	4	3	97.5	95.4	96.6
Dillmann-Arroyo et al, <sup>19</sup> 2011	—	—	27	20	6	1	0	100	88	96.3
Melendez-Alafort et al, <sup>20</sup> 2004	120	2.18	6	5	1	0	0	100	100	100
Fard-Esfahani et al, <sup>21</sup> 2010	—	—	15	6	—	—	9	40	—	—
Vallejo et al, <sup>22</sup> 2008	—	—	13	5	6	1	1	83.3	85.7	84.6
Summary			495	273	191	15	16	94.5 (91.2–96.8)	92.7 (88.3–95.9)	93.7 (91.2–95.7)

TP indicates true positive; TN, true negative; FP, false positive; FN, false negative; Se, sensitivity; Sp, specificity; Ac, accuracy.

from human UBI and which attaches preferentially to bacteria in vitro and not to activated leukocytes.<sup>25</sup> The <sup>99m</sup>Tc-UBI 29–41 scans have depicted the most promising results for delineation between infection and inflammation in animal models<sup>11,26,27</sup> and also in inadequate human investigations.<sup>12,13,15,16,18,19,28,29</sup>

Our meta-analysis showed that <sup>99m</sup>Tc-UBI 29–41 scans had a reasonably high differentiation ability in recognizing an infection among patients who had possible infection in the soft tissue, musculoskeletal system, and prosthesis. The overall accuracy was 93.7%.

The <sup>99m</sup>Tc-UBI 29–41 scan has been applied to the diagnosis of infection in limited clinical situations such as osteomyelitis and soft-tissue infections,<sup>15,16</sup> spondylitis,<sup>19</sup> fever of unknown origin,<sup>13</sup> prosthesis,<sup>17</sup> and endocarditis (which we used in limited cases); except for diabetic patients with a poor vascular bed,<sup>21</sup> high sensitivities and specificities were mentioned. Systematic assessment of diagnostic ability in these settings would be helpful to illustrate the most favorable spectrum of applications for this scintigraphic modality.

Consequently, <sup>99m</sup>Tc UBI 29–41, without localization in sterile inflammation and with an absence of immunological side effects, may be considered an option for leukocyte labeling, which is still applied as the gold standard for detection of infection in nuclear medicine. It can also be used in leukopenic patients. Furthermore, it was demonstrated that <sup>99m</sup>Tc-UBI (29–41) accumulation directly represents the number of viable bacteria, and it is applicable for the monitoring of antibiotic treatment.<sup>28,30</sup>

Furthermore, in all studies, the maximum contrast (A/N ratio) was obtained in the earliest time post-<sup>99m</sup>Tc-UBI injection.<sup>12,16</sup> These results may indicate a first pass-like distribution with strong avidity of the radiotracer in the trend of its targets, resulting in the easy diagnosis of infection as early as few minutes postinjection. In addition, <sup>99m</sup>Tc-UBI 29–41 scans illustrated rapid localization to the target region and fast renal clearance, with insignificant liver uptake and hepatobiliary excretion.<sup>12,16,20</sup>

In our meta-analysis, a number of reference standard methods were used in the studies, including cultures and other microbiologic examination, histopathologic examination, clinical follow-up examination, and radiologic examination in different combinations. None of these studies is perfect as a reference standard for confirming the diagnosis of infection. Miscategorization bias as a result of inadequate standard methods may have an effect on the estimation of the statistical parameters of a tested method, which may inflate or deflate its diagnostic ability. The mix of some standard methods in the studies, however, perhaps diminished this factor.

Although this meta-analysis showed good insight into using <sup>99m</sup>Tc-UBI in the diagnosis of infection, especially in musculoskeletal infection, it should be mentioned that it has some limitations.

The major limitations are the relatively small sample size with different underlying problems. The meta-analysis is much larger than the largest eligible study and indicates the need to include more large-scale evidence. The second limitation is the application of significant variability in the reference standard methods in the eligible studies and the nonperformance of statistical parameters according to the type of reference standard used, due to the lack of provision of separate results based on the reference standard in the eligible investigations. Third, the dosages of <sup>99m</sup>Tc, the time of scanning post-administration of UBI, the study designs, and the age groups varied throughout the studies, but it is uncertain how these factors might affect the results. Fourth, the interpretation of the <sup>99m</sup>Tc-UBI scan was based on qualitative or semiquantitative methods with 2 or 3 readers so that some diagnostic biases are to be anticipated. Fifth, even though we searched for all eligible studies, the fact that there were some missing studies was inevitable.

On the basis of the current study, <sup>99m</sup>Tc-UBI imaging appears to have distinct merits as a diagnostic method in the detection of infection, especially in the musculoskeletal system. However, it cannot yet fully substitute for the existing tests used for the diagnosis of infection, especially in diabetic patients.

## CONCLUSION

The study demonstrated that <sup>99m</sup>TcUBI scintigraphy can be used to identify an infectious process with 93.7% accuracy in early views; however, further investigations are recommended.

## REFERENCES

- Dams ET, Oyen WJ, Boerman OC, et al. <sup>99m</sup>Tc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. *J Nucl Med.* 2000;41:622–630.
- Calame W, Welling M, Feitsma HI, et al. Improved detection of a staphylococcal infection by monomeric and protein A-purified polyclonal human immunoglobulin. *Eur J Nucl Med.* 1993;20:490–494.
- Welling M, Feitsma HI, Calame W, et al. Localization of a bacterial infection with <sup>99m</sup>Tc-labelled human IgG: further improvement with enriched IgG subclass preparations. *Nucl Med Commun.* 1997;18:1057–1064.
- Hnatowich DJ, Virzi F, Ruszkowski M. Investigations of avidin and biotin for imaging applications. *J Nucl Med.* 1987;28:1294–1302.
- Britton KE, Vinjamuri S, Hall AV, et al. Clinical evaluation of technetium-99m infection for the localisation of bacterial infection. *Eur J Nucl Med.* 1997;24:553–556.
- Weon YC, Yang SO, Choi YY, et al. Use of Tc-99m HMPAO leukocyte scans to evaluate bone infection: incremental value of additional SPECT images. *Clin Nucl Med.* 2000;25:519–526.

7. Akhtar MS, Iqbal J, Khan MA, et al.  $^{99m}\text{Tc}$ -labeled antimicrobial peptide ubiqaicidin (29–41) accumulates less in *Escherichia coli* infection than in *Staphylococcus aureus* infection. *J Nucl Med*. 2004;45:849–856.
8. Signore A, Annovazzi A, Chianelli M, et al. Peptide radiopharmaceuticals for diagnosis and therapy. *Eur J Nucl Med*. 2001;28:1555–1565.
9. Welling MM, Visentin R, Feitsma HI, et al. Infection detection in mice using  $^{99m}\text{Tc}$ -labeled HYNIC and N2S2 chelate conjugated to the antimicrobial peptide UBI 29–41. *Nucl Med Biol*. 2004;31:503–509.
10. Lupetti A, Welling MM, Pauwels EK, et al. Radiolabelled antimicrobial peptides for infection detection. *Lancet Infect Dis*. 2003;3:223–229.
11. Welling MM, Lupetti A, Balter HS, et al.  $^{99m}\text{Tc}$ -labeled antimicrobial peptides for detection of bacterial and *Candida albicans* infections. *J Nucl Med*. 2001;42:788–794.
12. Gandomkar M, Najafi R, Shafiei M, et al. Clinical evaluation of antimicrobial peptide [( $^{99m}\text{Tc}$ )/Tricine/HYNIC(0)]ubiqaicidin 29–41 as a human-specific infection imaging agent. *Nucl Med Biol*. 2009;36:199–205.
13. Sepulveda-Mendez J, de Murphy CA, Rojas-Bautista JC, et al. Specificity of  $^{99m}\text{Tc}$ -UBI for detecting infection foci in patients with fever in study. *Nucl Med Commun*. 2010;31:889–895.
14. Critical Appraisal Skills Programme (CASP) and Evidence-based Practice: CASP qualitative appraisal tool. NHS Learning and Development. Available from: [www.phru.nhs.uk/learning](http://www.phru.nhs.uk/learning).
15. Assadi M, Vahdat K, Nabipour I, et al. Diagnostic value of  $^{99m}\text{Tc}$ -ubiqaicidin scintigraphy for osteomyelitis and comparisons with  $^{99m}\text{Tc}$ -methylene diphosphonate scintigraphy and magnetic resonance imaging. *Nucl Med Commun*. 2011;32:716–723.
16. Akhtar MS, Qaisar A, Irfanullah J, et al. Antimicrobial peptide  $^{99m}\text{Tc}$ -ubiqaicidin 29–41 as human infection-imaging agent: clinical trial. *J Nucl Med*. 2005;46:567–573.
17. Aryana K, Hootkani A, Sadeghi R, et al.  $^{99m}\text{Tc}$ -labeled ubiqaicidin scintigraphy. A promising method in hip prosthesis infection diagnosis. *Nuklearmedizin*. 2012;51:133–139.
18. Arteaga de Murphy C, Gemmel F, Balter J. Clinical trial of specific imaging of infections. *Nucl Med Commun*. 2010;31:726–733.
19. Dillmann-Arroyo C, Cantu-Leal R, Campa-Nunez H, et al. [Application of the ubiqaicidin 29–41 scan in the diagnosis of pyogenic vertebral osteomyelitis]. *Acta Ortop Mex J* 2011;25:27–31.
20. Melendez-Alafort L, Rodriguez-Cortes J, Ferro-Flores G, et al. Biokinetics of ( $^{99m}\text{Tc}$ )-UBI 29–41 in humans. *Nucl Med Biol*. 2004;31:373–379.
21. Fard-Esfahani A, Beiki D, Fallahi B, et al. Evaluation of  $^{99m}\text{Tc}$ -ubiqaicidin 29–41 scintigraphy in differentiation of bacterial infection from sterile inflammation in diabetic foot. *Iran J Nucl Med*. 2010;18:20–28.
22. Vallejo E, Martinez I, Tejero A, et al. Clinical utility of  $^{99m}\text{Tc}$ -labeled ubiqaicidin 29–41 antimicrobial peptide for the scintigraphic detection of mediastinitis after cardiac surgery. *Arch Med Res*. 2008;39:768–774.
23. Rennen HJ, Boerman OC, Oyen WJ, et al. Imaging infection/inflammation in the new millennium. *Eur J Nucl Med*. 2001;28:241–252.
24. Gemmel F, Dumarey N, Welling M. Future diagnostic agents. *Semin Nucl Med*. 2009;39:11–26.
25. Ferro-Flores G, Arteaga de Murphy C, Pedraza-Lopez M, et al. In vitro and in vivo assessment of  $^{99m}\text{Tc}$ -UBI specificity for bacteria. *Nucl Med Biol*. 2003;30:597–603.
26. Welling MM, Paulusma-Annema A, Balter HS, et al. Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations. *Eur J Nucl Med*. 2000;27:292–301.
27. Sarda-Mantel L, Saleh-Mghir A, Welling MM, et al. Evaluation of  $^{99m}\text{Tc}$ -UBI 29–41 scintigraphy for specific detection of experimental *Staphylococcus aureus* prosthetic joint infections. *Eur J Nucl Med Mol Imaging*. 2007;34:1302–1309.
28. Nazari B, Azizmohammadi Z, Rajaei M, et al. Role of  $^{99m}\text{Tc}$ -ubiqaicidin 29–41 scintigraphy to monitor antibiotic therapy in patients with orthopedic infection: a preliminary study. *Nucl Med Commun*. 2011;32:745–751.
29. Dillmann-Arroyo C, Cantu-Leal R, Campa-Nunez H, et al. [Application of the ubiqaicidin 29–41 scan in the diagnosis of pyogenic vertebral osteomyelitis]. *Acta Ortop Mex*. 2012;25:27–31.
30. Akhtar MS, Khan ME, Khan B, et al. An imaging analysis of ( $^{99m}\text{Tc}$ )-UBI (29–41) uptake in *S. aureus* infected thighs of rabbits on ciprofloxacin treatment. *Eur J Nucl Med Mol Imaging*. 2008;35:1056–1064.